WHO to Recommend Weight-Loss Drugs for Adults Globally

WHO's New Stance on Obesity Treatment

• 🌍 The World Health Organization (WHO) is set to officially back the use of weight-loss drugs for treating obesity in adults for the first time.
• 🗓️ This conditional recommendation will be released in August as part of new WHO guidelines on obesity treatment.
• 🧒 Separate guidelines are also being developed for children and adolescents.

Access and Cost Considerations

• ⚖️ The WHO is advocating for strategies to improve access to these treatments in low and middle-income countries, where a significant portion of the global obesity population resides.
• 💰 Medications like Novo Nordisk's WGOI and Eli Lilly's Zepbound, known as GLP-1 receptor agonists, can cost over $1,000 a month.
• ⏳ Studies suggest that continuous use may be necessary to maintain weight loss, potentially for the rest of a person's life.

Drug Efficacy and Market Impact

• 📉 In clinical trials, these drugs have shown significant weight loss, with individuals losing 15 to 20% of their body weight.
• 💡 The active ingredient in some newer drugs, semaglutide, is expected to come off patent in some markets next year.
• 📈 Strong sales of drugs like Zepbound have contributed to positive financial results for pharmaceutical companies, though market access can be complex, as seen with CVS Health's decision regarding reimbursement.